We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

50 hedge funds and large institutions have $12.8M invested in NeuBase Therapeutics, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

4% less funds holding

Funds holding: 52 → 50 (-2)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

44% less capital invested

Capital invested by funds: $22.9M → $12.8M (-$10M)

75% less call options, than puts

Call options by funds: $307K | Put options by funds: $1.24M

Holders
50
Holders Change
-2
Holders Change %
-3.85%
% of All Funds
1.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
9
Reduced
9
Closed
10
Calls
$307K
Puts
$1.24M
Net Calls
-$934K
Net Calls Change
-$2.63M

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$1.3M
2
B
Bailard
California
+$1.3M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$398K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$360K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$185K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$2.27M
2
PP
PDT Partners
New York
-$270K
3
Deutsche Bank
Deutsche Bank
Germany
-$255K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$172K
5
OAM
Oxford Asset Management
United Kingdom
-$161K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
26
T. Rowe Price Associates
Maryland
$86K – – –
CS
27
Credit Suisse
Switzerland
$84K +$92.6K +65 New
FNBT
28
FineMark National Bank & Trust
Florida
$73K – – –
CG
29
Cutler Group
California
$68K +$71.2K +50 +1,667%
WMC
30
Westwood Management Corporation
Illinois
$64K – – –
UBS Group
31
UBS Group
Switzerland
$54K -$35.6K -25 -37%
VKH
32
Virtu KCG Holdings
New York
$48K +$54.1K +38 New
Morgan Stanley
33
Morgan Stanley
New York
$47K -$29.9K -21 -37%
Citadel Advisors
34
Citadel Advisors
Florida
$39K +$27.1K +19 +173%
State Street
35
State Street
Massachusetts
$33K – – –
Millennium Management
36
Millennium Management
New York
$33K +$35.6K +25 New
WSFS
37
Wilmington Savings Fund Society
Delaware
$32K – – –
First Manhattan
38
First Manhattan
New York
$23K – – –
Creative Planning
39
Creative Planning
Kansas
$20K -$18.5K -13 -46%
Bank of Montreal
40
Bank of Montreal
Ontario, Canada
$16K – – –
BIM
41
BlackRock Investment Management
Delaware
$15K – – –
CLOS
42
Compagnie Lombard Odier SCmA
Switzerland
$13K – – –
BA
43
BlackRock Advisors
Delaware
$11K – – –
AIM
44
Advantage Investment Management
Iowa
$6K – – –
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
$6K – – –
TRCT
46
Tower Research Capital (TRC)
New York
$4K +$1.43K +1 +33%
Bank of America
47
Bank of America
North Carolina
$2K -$5.7K -4 -80%
Wells Fargo
48
Wells Fargo
California
$1K – – –
LTFS
49
Ladenburg Thalmann Financial Services
Florida
$1K +$1.43K +1 New
Geode Capital Management
50
Geode Capital Management
Massachusetts
$490 +$19.9K +14 +4%
1
2
3

NBSE Hedge Fund Activity: Q1 2016 in Review

50 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2016, worth a combined $12.8M — down 44% from $22.9M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of NBSE and 8 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 9 added.

The largest buyer was Opaleye Management, opening a new position worth an estimated $1.3M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $2.27M sold.

  • 50 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2016, down from 52 in Q4 2015.
  • Funds reported $12.8M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2016, down 44% quarter-over-quarter.
  • 8 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2016 and 10 closed out, a net change of -2 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2016 was Opaleye Management, an estimated $1.3M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2016 was Baker Bros. Advisors, an estimated $2.27M sold.

Based on aggregated 13F filings for Q1 2016.